Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Renin: friend or foe?
M. J Brown
Heart (2007) Vol. 93, Iss. 9, pp. 1026-1033
Open Access | Times Cited: 83

Showing 1-25 of 83 citing articles:

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
Bryan Williams, Thomas M. MacDonald, S. V. Morant, et al.
The Lancet (2015) Vol. 386, Iss. 10008, pp. 2059-2068
Open Access | Times Cited: 1066
Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies
Seema Patel, Abdur Rauf, Haroon Khan, et al.
Biomedicine & Pharmacotherapy (2017) Vol. 94, pp. 317-325
Closed Access | Times Cited: 500
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies
Bryan Williams, Thomas M. MacDonald, S. V. Morant, et al.
The Lancet Diabetes & Endocrinology (2018) Vol. 6, Iss. 6, pp. 464-475
Open Access | Times Cited: 232
Current best practice in the management of hypertensive disorders in pregnancy
Asma Khalil, Patrick O’Brien, Rosemary Townsend
Integrated Blood Pressure Control (2016) Vol. Volume 9, pp. 79-94
Open Access | Times Cited: 181
Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial
Morris J. Brown, Gordon T. McInnes, Cheraz Cherif Papst, et al.
The Lancet (2011) Vol. 377, Iss. 9762, pp. 312-320
Closed Access | Times Cited: 167
New Drugs and Technologies
Nathalie Bergeron, Binh An P. Phan, Yunchen Ding, et al.
Circulation (2015)
Open Access | Times Cited: 92
The Renin–Angiotensin System and Cardiovascular–Kidney–Metabolic Syndrome: Focus on Early-Life Programming
You‐Lin Tain, Chien‐Ning Hsu
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3298-3298
Open Access | Times Cited: 16
Novel pharmacological approaches to lowering blood pressure and managing hypertension
Matthew Sayer, David J. Webb, Neeraj Dhaun
Nature Reviews Cardiology (2025)
Closed Access | Times Cited: 1
Differential associations between renal function and “modifiable” risk factors in patients with chronic heart failure
Tom D.J. Smilde, Kevin Damman, Pim van der Harst, et al.
Clinical Research in Cardiology (2008) Vol. 98, Iss. 2, pp. 121-129
Closed Access | Times Cited: 118
Aliskiren
Morris J. Brown
Circulation (2008) Vol. 118, Iss. 7, pp. 773-784
Open Access | Times Cited: 110
Postpartum management of hypertension
Kate Bramham, Catherine Nelson‐Piercy, Morris J. Brown, et al.
BMJ (2013) Vol. 346, Iss. feb25 1, pp. f894-f894
Closed Access | Times Cited: 77
Association of Antihypertensives That Stimulate vs Inhibit Types 2 and 4 Angiotensin II Receptors With Cognitive Impairment
Zachary A. Marcum, Jordana B. Cohen, Chong Zhang, et al.
JAMA Network Open (2022) Vol. 5, Iss. 1, pp. e2145319-e2145319
Open Access | Times Cited: 35
Low- and High-renin Heart Failure Phenotypes with Clinical Implications
Noémi Pávó, Georg Goliasch, Raphael Wurm, et al.
Clinical Chemistry (2017) Vol. 64, Iss. 3, pp. 597-608
Open Access | Times Cited: 59
A meta-analysis of add-on use of spironolactone in patients with resistant hypertension
Di Zhao, Hui Liu, Pingshuan Dong, et al.
International Journal of Cardiology (2016) Vol. 233, pp. 113-117
Closed Access | Times Cited: 53
The Pharmacogenomic and Metabolomic Predictors of ACE Inhibitor and Angiotensin II Receptor Blocker Effectiveness and Safety
Hania K. Flaten, Andrew A. Monte
Cardiovascular Drugs and Therapy (2017) Vol. 31, Iss. 4, pp. 471-482
Open Access | Times Cited: 43
Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?
Flavio Cadegiani
AJP Endocrinology and Metabolism (2020) Vol. 318, Iss. 5, pp. E587-E588
Open Access | Times Cited: 35
Association of Angiotensin II–Stimulating Antihypertensive Use and Dementia Risk
Jan Willem van Dalen, Zachary A. Marcum, Shelly L. Gray, et al.
Neurology (2020) Vol. 96, Iss. 1
Open Access | Times Cited: 34
Adipose tissue (P)RR regulates insulin sensitivity, fat mass and body weight
Zulaykho Shamansurova, Paul Tan, Basma A. Ahmed, et al.
Molecular Metabolism (2016) Vol. 5, Iss. 10, pp. 959-969
Open Access | Times Cited: 36
Renin Activity in Heart Failure with Reduced Systolic Function—New Insights
Ryan D. Sullivan, Radhika M. Mehta, Ranjana Tripathi, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 13, pp. 3182-3182
Open Access | Times Cited: 35
Benefits and Risks of Continuing Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Antagonists, and Mineralocorticoid Receptor Antagonists during Hospitalizations for Acute Heart Failure
Estefanía Oliveros, Ebenezer Oni, Anum Shahzad, et al.
Cardiorenal Medicine (2020) Vol. 10, Iss. 2, pp. 69-84
Open Access | Times Cited: 28
Comparative effects of angiotensin II stimulating and inhibiting antihypertensives on dementia risk: a systematic review and meta-analysis
Eyayaw Ashete Belachew, Gregory M. Peterson, Woldesellassie M. Bezabhe
GeroScience (2025)
Open Access
Blood pressure response to mineralocorticoid receptor antagonists or aldosterone synthase inhibitors according to baseline renin levels
Ana Rita Leite, António Angélico‐Gonçalves, Adelino Leite‐Moreira, et al.
Journal of Human Hypertension (2025)
Closed Access
Aliskiren Monotherapy Results in the Greatest and the Least Blood Pressure Lowering in Patients With High- and Low-Baseline PRA Levels, Respectively
Alice Stanton, Patrick Dicker, Eoin O’Brien
American Journal of Hypertension (2009) Vol. 22, Iss. 9, pp. 954-957
Closed Access | Times Cited: 36
Success and failure of vaccines against renin–angiotensin system components
Morris J. Brown
Nature Reviews Cardiology (2009) Vol. 6, Iss. 10, pp. 639-647
Closed Access | Times Cited: 33
Plasma renin and outcome in the community: data from PREVEND
Rudolf A. de Boer, Nicolas F. Schroten, S. J. L. Bakker, et al.
European Heart Journal (2012) Vol. 33, Iss. 18, pp. 2351-2359
Open Access | Times Cited: 30
Page 1 - Next Page

Scroll to top